GTC-Hematology Profile Plus combines expression and fusion with mutation analysis in DNA and RNA. The test covers 177 DNA genes and 1408 RNA genes. This is a comprehensive evaluation of all hematologic neoplasms. However, it is especially recommended for:
-Acute Lymphoblastic Leukemia (ALL): This comprehensive assay is designed to confirm the diagnosis of Ph-ALL and Ph-like ALL and distinguish them from other types of ALL. It can be used for diagnosis as well as for monitoring. Ph-like ALL is detected in 20% to 25% of adult ALL and in 15% of pediatric ALL. Diagnosis of Ph+-ALL and Ph-like ALL is very important because TKI therapy can be helpful in most of these patients. This assay can determine most of the mutations, translocations, and expression of genes (CRLF2) associated with Ph+ ALL and Ph-like ALL.
-Diffuse Large B-cell Lymphoma (DLBCL) and other Lymphoma: This assay can provide very valuable information for the management and monitoring of patients with DLBCL. It can distinguish between ABC and GCB and can help in the diagnosis of double hit lymphoma. The assay is also useful for follicular lymphoma and T-cell neoplasms.
-Acute Myeloid Leukemia (AML): Translocations in AML are very important for diagnosis, prognosis and selecting therapy. This comprehensive testing can provide a complete evaluation of fusion mRNA and mutations. It also helps in determining a diagnosis in acute leukemia with ambiguous phenotype.
Turn Around Time: 5-7 Days DNA, 7-10 Days RNA
- Bone marrow: 2 mL. EDTA tube is preferred.
- Peripheral blood: 5-10 mL. EDTA tube is preferred.
- Fresh Tissue
- FFPE: 1 H&E slide and 8-10 unstained slides, 5-7 microns of BM clot or tissue fixed with 10% NBF fixative. Alternatively, the FFPE block of the BM clot can be sent for sectioning in our Lab.
Specimen Preparation and Shipping Guidelines
Use the Hematology Transport Kit or Solid Tumor Transport Kit (depending on the sample type)
- Complete Requisition, making sure all sections are completed in their entirety including client information, patient Information, specimen Information and test Selection. Missing information may delay reporting of test results.
- Diagnosis/patient history is extremely important in rendering the correct interpretation of results and should also be filled out as completely as possible. A copy of a Path report should be included.
- Ensure the specimen is labeled with patient name and number. A minimum of two patient identifiers is required for each specimen
For FFPE samples:
- If sending FFPE Block-Insert up to 6 blocks into plastic block tray provided. Insert block tray into foam insert in the transport box.
- If sending slides-Insert slides into plastic slide holders provided. Insert the slide holders into the foam insert in the transport box. The container will hold up to 6 maximum slide holders.
- Place folded test requisition(s) and/or manifest(s) if ordered electronically into the transport kit.
- Close box and tuck tabs into place. No tape necessary.
For blood samples:
- Ship using a cold pack. The cold pack should not directly contact the blood tube. Ship as soon as sample collected with overnight delivery.
Genes validated and tested for Mutations in DNA testing for hematology
Genes Tested for Fusion, Expression, and Mutations
ABL1 EGFR GLI1 NTRK2 RHOA AKT3 ERG HMGA2 NTRK3 ROS1 ALK ETV6 IKZF3 NUP214 RUNX1 BCL1 EWSR1 JAK2 NUP98 RUNX1T1 BCL2 FGFR1 KIAA1549 PDGFRA SS18 BCL6 FGFR2 KMT2A PDGFRB STAT6 BRAF FGFR3 MAP3K1 PD-L1 TAFG CAMTA1 FIP1L1 MECOM PICALM TAL1 CBFB FLAG1 MYC PML TCF3 CIC FOXO1 NOTCH1 RARA TFG CREBBP FUS NTRK1 RET YWHAE
How to complete the Genomic Testing Cooperative requisition form.
Keep in mind that we do not accept blood samples directly from individuals. Talk with your M.D. to fill out the form for you.